Recombinant Proteins iso9001 ISO13485
搜索
 > 【LILRB1】重组蛋白信息

LILRB1信息

英文名称:Leukocyte immunoglobulin-like receptor B1
中文名称:白细胞免疫球蛋白样受体B1
靶点别称:Leukocyte Immunoglobulin Like Receptor B1,LIR-1,MIR-7,ILT2,LIR1,Myeloid Inhibitory Receptor 7,Leucocyte Ig-Like Receptor B1,ILT-2,CD85j Antigen,Ig-Like Transcript 2,PIR-B,Leukocyte Immunoglobulin-Like Receptor, Subfamily B (With TM And ITIM Domains), Memb
上市药物数量:0
临床药物数量:1
最高研发阶段:临床二期

LILRB1产品列表

货号 物种 产品描述 蛋白结构 纯度 活性
CDJ-H5252
Human
Human LILRB1 / CD85j / ILT2 Protein, Fc Tag
CDJ-H82F7
Human
Biotinylated Human LILRB1 / CD85j / ILT2 Protein, Fc,Avitag
 
评论(0)
 

LILRB1 分子别名

CD85J,LILRB1,CD85,ILT2,LIR1,MIR7

LILRB1 分子背景

CD85 antigen-like family member J (CD85J) is also known as Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1 or LIR-1), Immunoglobulin-like transcript 2 (ILT-2), Monocyte/macrophage immunoglobulin-like receptor 7 (MIR7), which belongs to leukocyte immunoglobulin-like receptor (LIR) family. CD85J / LILRB1 Contains 4 Ig-like C2-type (immunoglobulin-like) domains. CD85J / LIR-1 is expressed predominantly on B-cells and monocytes. CD85J is receptor for class I MHC antigens and recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles and is also receptor for H301/UL18, a human cytomegalovirus class I MHC homolog. Ligand binding results in inhibitory signals and down-regulation of the immune response. CD85J / LILRB1 interaction with HLA-B or HLA-E leads to inhibition of the signal triggered by FCER1A and inhibits serotonin release. CD85J / LILRB1 inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions.

LILRB1 参考文献

LILRB1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
BND-22 BND-22 临床二期 Biond Biologics Ltd 实体瘤, 肿瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定